In the United States, where the health system maintains a strong structural bias toward rapid access once the regulator approves a therapy, the 44-day outcome translates into virtually immediate insured access for more than 90 per cent of Americans through a mix of private and public coverage.
FDA approved new cancer therapy and delivers patient access in just 44 days
March 3, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Novo Nordisk backs care for rural health professionals in southern NSW
August 19, 2026 - - Latest News -
Opportunity #3 - finally deliver on the repeated claims of patient-centricity
August 19, 2026 - - Latest News -
Departmental restructure formally splits medicines financing from pharmacy services
August 19, 2026 - - Latest News -
Wesfarmers Health evolves its loyalty program with new Pulse Rewards
August 19, 2026 - -
CSL absorbs loss in reset year as investors back its plasma-led recovery
August 18, 2026 - - Latest News -
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - - Latest News -
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - - Latest News

